BACKGROUND: Randomized controlled trials (RCTs) of duloxetine (DLX), an inhibitor of both norepinephrine and serotonin transporters (SNRI), have tested its efficacy in acute major depressive disorder (MDD) versus placebo (PBO) or standard serotonin-reuptake inhibitors (SRIs) and require review, comparing analytical methods. METHOD: Computerized searching to identify reports of RCTs of DLX in adult, acute MDD patients permitted meta-analytic pooling to estimate overall response and remission rates, to compare mixed-model, repeated measures (MMRM) versus last-observations-carried-forward (LOCF) analytical methods, and to assess relations of DLX dose to efficacy and adverse outcomes. RESULTS: We identified 17 RCTs involving 22 comparisons (DLX versus PBO [n = 17) and DLX versus an SRI [n = 16]), based on MMRM and LOCF methods that allowed estimates of response (>or=50% improvement of depression scores) or remission (final depression score <or=7). There was a large overall DLX/PBO contrast (LOCF, RR = 1.42 [CI: 1.31-1.53], p < 0.0001, with a success rate of 65% [11/17]), and somewhat larger effects with MMRM in both response (MMRM: RR = 1.48 [95%CI: 1.31-1.66] versus LOCF: RR = 1.41 [CI: 1.28-1.56]; NNT 4.8 versus 6.5) and remission (MMRM: RR = 1.61 [CI: 1.41-1.85] versus LOCF: RR = 1.44 [CI: 1.27-1.63]; NNT = 5.9 versus 8.9). Based on LOCF methods, dropout rates were similar with DLX and PBO (RR = 1.04 [CI: 0.94-1.15]); DLX response was dose-dependent (r = +0.72, p = 0.001), and RCT-dropout rates were inversely related to DLX dose, but possibly artifactually. LIMITATIONS: RCTs involving DLX are limited, with few direct comparisons to standard antidepressants. CONCLUSIONS: DLX has good evidence of efficacy in acute, adult MDD, especially at doses of 80-120 mg/day, but remains inadequately tested against standard alternatives. MMRM analyses yielded slightly superior FLX/PBO contrasts than older LOCF methods.

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods / Pompili, Maurizio; Girardi, Paolo; Innamorati, Marco; Mancini, Michele; Serafini, Gianluca; Mazzarini, Lorenzo; Del Casale, Antonio; Tatarelli, Roberto; Baldessarini, Ross J. - In: HUMAN PSYCHOPHARMACOLOGY. - ISSN 0885-6222. - STAMPA. - 24:3(2009), pp. 177-190. [10.1002/hup.1005]

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

POMPILI, Maurizio;Girardi, Paolo;Innamorati, Marco;Mancini, Michele;Serafini, Gianluca;Mazzarini, Lorenzo;Del Casale, Antonio;Tatarelli, Roberto;
2009

Abstract

BACKGROUND: Randomized controlled trials (RCTs) of duloxetine (DLX), an inhibitor of both norepinephrine and serotonin transporters (SNRI), have tested its efficacy in acute major depressive disorder (MDD) versus placebo (PBO) or standard serotonin-reuptake inhibitors (SRIs) and require review, comparing analytical methods. METHOD: Computerized searching to identify reports of RCTs of DLX in adult, acute MDD patients permitted meta-analytic pooling to estimate overall response and remission rates, to compare mixed-model, repeated measures (MMRM) versus last-observations-carried-forward (LOCF) analytical methods, and to assess relations of DLX dose to efficacy and adverse outcomes. RESULTS: We identified 17 RCTs involving 22 comparisons (DLX versus PBO [n = 17) and DLX versus an SRI [n = 16]), based on MMRM and LOCF methods that allowed estimates of response (>or=50% improvement of depression scores) or remission (final depression score
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/228594
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 60
social impact